Something historic began in early 2026 in a Boston laboratory — and its ripple effects could eventually reach every American who dreads the physical decline of aging.
Life Biosciences, a biotechnology company co-founded by Harvard genetics professor Dr. David Sinclair, announced on January 28, 2026, that the U.S. Food and Drug Administration cleared its Investigational New Drug application for a therapy called ER-100 — making it the first cellular rejuvenation treatment using partial epigenetic reprogramming ever cleared for testing in human beings.
The company has now begun Phase 1 enrollment, targeting patients with two serious eye conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). Both conditions cause progressive, often irreversible vision loss by damaging retinal ganglion cells — the nerve cells that carry visual signals from the eye to the brain.
The stakes are high. An estimated 3 million Americans have glaucoma, and tens of thousands are diagnosed with NAION each year. For most of them, the damage is considered permanent. ER-100's promise is nothing short of extraordinary: injecting "rejuvenation instructions" directly into damaged eye cells to help restore their function by rewinding their biological clock.
For the research community, however, the significance extends far beyond ophthalmology.
What Epigenetic Reprogramming Actually Does
To understand why this trial is being called a seismic event in medicine, it helps to understand what epigenetic reprogramming means — and why scientists have been pursuing it for over a decade.
Every cell in the human body carries the same DNA. What determines whether a cell is young and healthy versus old and dysfunctional is not the DNA sequence itself but a layer of chemical "tags" sitting on top of it — the epigenome. As we age, these tags accumulate errors, silencing genes that should be active and activating genes that should be quiet. The result is cellular aging: reduced regenerative capacity, chronic inflammation, impaired metabolism, and eventually, disease.
Partial epigenetic reprogramming — the technique behind ER-100 — uses a controlled, limited form of genetic signaling to reset those tags without erasing the cell's core identity. The goal is to make an old, damaged cell behave the way it did when it was younger, without turning it back into an undifferentiated stem cell (which would carry cancer risk).
In mouse studies, the approach has shown striking results: restoring vision, improving muscle and liver function, and reversing markers of biological aging. The question the Life Biosciences trial will begin to answer is whether those results translate to human beings.
"This is a huge milestone for the entire partial reprogramming field," said Yuri Deigin, CEO of YouthBio Therapeutics, which is developing its own reprogramming-based Alzheimer's therapy. "It's also a strong signal for the broader longevity space that regulators are increasingly willing to evaluate therapies that aim to modify upstream epigenetic drivers of aging, rather than only treating downstream symptoms."
Life Biosciences CEO Jerry McLaughlin called the FDA clearance "a transformational day" for the field when speaking to Fortune.
What the Trial Will Actually Test — and What Comes Next
The Phase 1 trial is primarily a safety study. Researchers will inject ER-100 directly into the eye, delivering rejuvenation instructions to retinal ganglion cells. By limiting the delivery to a single, accessible tissue, the team can monitor for any adverse effects — including the theoretical risk of off-target cell changes — with close precision before ever considering systemic administration.
The trial is expected to produce initial safety data by late 2026 or early 2027, according to McLaughlin. If safety is confirmed, the company plans to expand the therapy's applications across a broader pipeline of age-related diseases, leveraging ER-100's Partial Epigenetic Reprogramming (PER) platform.
The FDA's willingness to clear this IND application is itself noteworthy. Longevity researchers at Lifespan.io noted that regulators appear increasingly open to evaluating therapies that address the biological mechanisms of aging — not just the diseases it causes. That shift in regulatory philosophy could have broad consequences for how future anti-aging treatments are approved and funded.
Beyond the immediate trial, researchers are watching closely for what the first human data will say about epigenetic clock reversal. Epigenetic clocks — molecular tools that estimate biological age based on DNA methylation patterns — are expected to serve as biomarkers throughout the study, potentially providing the first real-world human evidence of age reversal at a cellular level.
Who Is Most at Risk — and Who Could Eventually Benefit
In the short term, the patients most immediately relevant to this trial are the roughly 3 million Americans living with open-angle glaucoma and the estimated 1,500 to 8,000 diagnosed with NAION annually. Both groups currently face limited treatment options and progressive, often untreatable vision loss. For them, ER-100 represents a potential first-of-its-kind intervention.
In the long term, the implications of a successful human reprogramming trial reach far beyond the eye. If the therapy proves safe and effective in this narrow tissue application, the scientific rationale for testing it in age-related conditions affecting the brain, muscle, heart, and other organs becomes considerably stronger.
Americans ages 30 to 50 — the demographic most actively searching for longevity solutions — are watching this trial as a bellwether for the broader field. The therapy is not available to the general public and may not be for years. But as the first human study, it marks a concrete transition from the realm of theoretical biology into verifiable clinical medicine.
Who Gets Access If It Works?
The trial's significance raises a question that longevity researchers and ethics boards are already wrestling with: if partial reprogramming therapies eventually prove safe and effective, who will be able to afford them?
Gene therapy treatments in the U.S. already carry price tags in the hundreds of thousands to millions of dollars per patient. The infrastructure for manufacturing, delivering, and monitoring reprogramming therapies could place them firmly in that category — at least initially. Medical ethicists have raised concerns, documented in peer-reviewed longevity forums, about whether access equity will be built into the development pipeline, or whether the first generation of rejuvenation therapies will remain available only to those with extraordinary financial resources.
Life Biosciences has not yet addressed pricing publicly, as the therapy remains in early-stage testing. But given the historical pattern of gene therapy costs in the U.S., this is a conversation the medical community — and patients — will need to have well before any approval is sought.
What Epigenetic Reprogramming Is, in Plain Language
Epigenetic reprogramming works by modifying the chemical markers that control how genes are expressed inside a cell. Unlike gene editing (which changes the underlying DNA sequence), reprogramming leaves the DNA intact and instead resets the instructions the cell follows. In older or damaged cells, these instructions have drifted from their original "young" state. Partial reprogramming nudges them back.
The "partial" in partial reprogramming is critical. Full reprogramming would take a cell all the way back to an embryonic state — which is scientifically useful for stem cell research but dangerous in a living body because it can cause cancer. Partial reprogramming stops short of that point, aiming for cellular rejuvenation without loss of cell identity.
Symptoms treated in this trial (vision loss from glaucoma or NAION) typically include progressive blurring, reduced peripheral vision, and, in advanced cases, severe central vision loss. There is currently no approved treatment that reverses established optic nerve damage.
Frequently Asked Questions
What is the Life Biosciences ER-100 trial testing? The trial is testing whether a gene therapy using partial epigenetic reprogramming can safely treat vision loss caused by glaucoma or optic neuropathy. It is the first human trial ever using this cellular rejuvenation approach.
What is partial epigenetic reprogramming? It is a process that resets the chemical markers controlling gene activity inside a cell, making older or damaged cells function more like younger, healthier ones — without altering the underlying DNA.
Who is eligible for this trial? Patients with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy (NAION) who meet the trial's medical eligibility requirements. The public should contact Life Biosciences or consult with an ophthalmologist to inquire about participation.
Is this therapy available to the public? No. ER-100 is in Phase 1 clinical testing only. It is not FDA-approved and is not available outside the trial. Broader availability, if approved, would be years away.
Does this mean scientists can reverse aging in humans? This trial will test safety first. Whether it also produces measurable reversal of biological age markers in human tissue will be a secondary finding. Scientists caution that mouse results do not always translate to humans, and definitive conclusions about aging reversal in people require much larger studies.
